Flexible Subscriptions to Match your Budget and Timeline See Plans and Pricing

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Express Scripts
Merck
AstraZeneca
McKesson
Baxter

Last Updated: December 3, 2021

DrugPatentWatch Database Preview

Litigation Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The small molecule drugs covered by the patents cited in this case are ⤷  Try it Free , ⤷  Try it Free , and ⤷  Try it Free .
Biologic Drugs cited in Amgen Inc. v. Amneal Pharmaceuticals
The biologic drug covered by the patents cited in this case is ⤷  Try it Free .

Details for Amgen Inc. v. Amneal Pharmaceuticals (D. Del. 2016)

Date Filed Document No. Description Snippet Link To Document
2016-12-14 14 Status Report and/or (c). Amgen also owns U.S. Patent No. 6,011,068, which is listed in the Orange Book listing…undergo parathyroidectomy. U.S. Patent No. 9,375,405 (the “’405 patent”) is listed in Approved Drug Products…‘405 patent invalid. 2. A judgment that no asserted claim of the ‘405 patent is infringed…Substance of the Actions These are Hatch-Waxman patent infringement actions relating to cinacalcet hydrochloride…United States prior to the expiration of the ’405 patent. By letter dated August 5, 2016, Aurobindo notified External link to document
2018-03-23 348 Consent Judgment admitted that Amgen’s United States Patent Number 9,375,405 (the “Amgen Patent”) is enforceable and valid. … Settlement Agreement, would infringe the Amgen Patent. 5. Defendants, including any of its successors…successors and assigns, are enjoined under the ’405 patent, and under any extensions and/or additional periods… or becomes entitled, from infringing the Amgen Patent, on its own part or through any Afflliate, by making…22 September 2016 1:16-cv-00853 830 Patent None District Court, D. Delaware External link to document
2018-04-19 357 Memorandum Opinion Defendants infringed United States Patent No. 9,375,405 (“the ’405 patent”) titled “Rapid Dissolution Formulation… 1. The ’405 Patent The ’405 patent issued from U.S. Patent Application No. 12/942,…OPINION This is a consolidated case for patent infringement brought by Plaintiff Amgen Inc. (…construed the meaning of the Markush groups in the ’405 patent; and (ii) Zydus’ Motion in Limine to preclude …case will be decided based on claim 1 of the ’405 patent, which states: (1) A pharmaceutical External link to document
2018-07-27 375 Opinion accord D.I. 353 at 182:10-183:4). C. Prosecution of the ’405 Patent 1. …consolidated patent infringement action arising under the Drug Price Competition and Patent Term Restoration…Hatch-Waxman Act. United States Patent No. 9,375,405 (the “’405 patent”) is assigned to Plaintiff Amgen…BACKGROUND A. The ’405 Patent The ’405 patent, entitled “Rapid Dissolution Formulation… was issued by the United States Patent and Trademark Office (“Patent Office”) on June 28, 2016. (D.I External link to document
2018-07-27 376 Order -12, and 14-18 of United States Patent No. 9,375,405 ('the '405 patent"); 2. Piramal does not infringe…20 of the '405 patent; and 4. Zydus does not infringe claims 18 and 20 of the 405 patent; but 5. Zydus … it, which are claims 1-6 and 8- 20 of the '405 patent; 3. Watson does not infringe any of the claims …infringe claims 1-4, 6, 8-9, 15-17, and 19 of the 405 patent, to the extent each claim is found valid and enforceable…22 September 2016 1:16-cv-00853 830 Patent None District Court, D. Delaware External link to document
2018-08-24 384 Order infringed claims of United States Patent No. 9,375,405 (the “’405 patent”). (D.I. 293, EX. 2 at 11 25-26…NON-INFRINGEMENT of claims 1-4, 6, 8-12, and 14-18 of the '405 patent shall be entered in favor of Amneal and against…NON-INFRINGEMENT of claims 1-6 and 8-20 of the '405 patent shall be entered in favor of Piramal and against…NON-INFRINGEMENT of claims 1-6 and 8-20 of the '405 patent shall be entered in favor of Watson and against…, § Defendants. § ORDER This is a consolidated patent infringement action Whereby plaintiff Amgen, Inc External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

AstraZeneca
Mallinckrodt
Harvard Business School
Moodys
McKesson
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.